Immune Checkpoint Inhibitor‐Related Bullous Pemphigoid: Distinct Clinical and Immunological Profiles
Experimental Dermatology · 2026
DOI: 10.1111/exd.70241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Dermatology, 2026. Verfasst von Min Zou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: the Science and Technology Program of Sichuan Province.
Abstract (Originalsprache)
Bullous pemphigoid (BP) induced by immune checkpoint inhibitors (ICI‐BP) is a rare immune‐related adverse event that affects patient prognosis and management; however, comparative data between ICI‐BP and non‐ICI BP, especially the dynamic changes of antibodies remain scarce. Therefore, we conducted this study to compare clinical presentation, immunological profile, treatment, management, and outcomes of ICI‐BP versus non‐ICI BP. This was a retrospective, single‐centre cohort study of consecutive patients between 2019 and 2025. Patients with ICI‐BP (Group A) were compared with Group B (BP with concurrent malignancy but no ICI exposure) and Group C (classic BP). There were 34, 10, and 68 patients enrolled in Groups A, B, and C, respectively (median follow‐up 24.5 months, IQR 10.8–50.0). ICI‐BP presented at a younger age (median, 59.0 years; IQR, 53.3–69.5; p < 0.001) and showed a marked male predominance (88.2%; p = 0.003). A transient, albeit non‐significant, rise in anti‐BP180 reactivity was observed during the first 2 months in ICI‐BP. Systemic glucocorticoids were required more frequently in ICI‐BP, and IL‐4 inhibitors demonstrated superior potency in accelerating BP180 antibody decline compared to non‐systematic therapy. Tumour response rates were similar between Groups A and B, as was mortality across the three groups. In conclusion, ICI‐BP differs from non‐ICI BP in clinical and immunological features and more often necessitates systemic glucocorticoid therapy, while IL‐4 inhibitors potentially expedite the reduction of anti‐BP180 antibodies in ICI‐BP patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Dermatology & Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China.
- The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Min Zou, Xun Feng, Tong Li, Yue Xiao, Wei Yan, Wei Li
Förderung
- the Science and Technology Program of Sichuan Province
Zitieren
APA
Zou, M., Feng, X., Li, J., Li, T., Wang, Y., Li, L., Peng, G., Wei, M., Teng, Y., Zhan, K., Wang, H., Xiao, Y., Yan, W., & Li, W. (2026). Immune Checkpoint Inhibitor‐Related Bullous Pemphigoid: Distinct Clinical and Immunological Profiles. Experimental Dermatology. https://doi.org/10.1111/exd.70241
Vancouver
Zou M, Feng X, Li J, Li T, Wang Y, Li L, et al. Immune Checkpoint Inhibitor‐Related Bullous Pemphigoid: Distinct Clinical and Immunological Profiles. Experimental Dermatology. 2026. doi:10.1111/exd.70241
BibTeX
@article{Zou2026,
author = {Zou, Min and Feng, Xun and Li, Jishu and Li, Tong and Wang, Yiyi and Li, Luyuan and Peng, Guo and Wei, Mintong and Teng, Yi and Zhan, Kun and Wang, Hongli and Xiao, Yue and Yan, Wei and Li, Wei},
title = {Immune Checkpoint Inhibitor‐Related Bullous Pemphigoid: Distinct Clinical and Immunological Profiles},
journal = {Experimental Dermatology},
year = {2026},
doi = {10.1111/exd.70241}
}
EUVIMED